Associated PressImportant note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.
Click here to return to Associated Press main menu

Leader of Senegal Aid Group Is Fired Over Drug Charges

Associated Press - October 15, 2002


DAKAR, Senegal -- Senegal's president said he has dismissed the head of a humanitarian organization for his alleged role in trafficking cheap AIDS drugs that were meant to go to Africa but were sold off in Europe.

Latif Gueye "committed extremely serious errors," President Abdoulaye Wade said on national television, announcing Mr. Gueye's removal from Africa helps Africa.

"I think that it is unfortunate that medicine meant for African AIDS patients is diverted and sold at higher prices in Europe," Mr. Wade said in his announcement Monday night.

Fifty-one countries are members of Africa Helps Africa, an intergovernmental humanitarian agency. A senior government official, who spoke on condition of anonymity, said that as head of the agency, Mr. Gueye was responsible for finding cheap drugs for Senegalese infected with the HIV virus that causes AIDS.

The official said Mr. Gueye allegedly sold the AIDS drugs in Europe, and that some were found in Holland and Germany.

Newspapers reported Tuesday that Mr. Gueye denied the allegations. His secretary said he planned to hold a press conference Tuesday afternoon.

Earlier this month, Dutch health authorities scrambled to recover illegally imported AIDS medication. Around 36,000 boxes of Combivir and Epivir, intended for sale at sharply reduced prices in Africa, ended up on pharmacy shelves in the Netherlands and Germany, said Raymond Salet, a spokesman for the Netherlands General Health Inspection Service.

Several multinational pharmaceutical companies have begun cutting prices on HIV medication in AIDS-ravaged Africa after criticism that they were making windfall profits at the expense of the poor. A box of 60 Combivir tablets that costs around €90 ($88) in Africa can be sold in Europe for €400 ($392).

In London, a spokesman for pharmaceutical firm GlaxoSmithKline PLC said they are cooperating with a European-based inquiry into Africa-bound antiretroviral drugs that were redirected to Europe.

"We are cooperating with the regulatory authorities, mainly the Dutch authorities because they took the lead," the spokesman said.

Senegal has managed to avoid the worst of the AIDS epidemic gripping Africa. On a continent that accounts for more than 70% of the world's 36 million people living with the AIDS virus, and where the infection rate in many nations runs in double digits, Senegal's HIV rate is less than 2%.

Health officials believe the West African country has been shielded in part by widely held cultural and religious values that limit sex to marriage.

021015
AP021015


Copyright © 2002 - Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .